AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1677502 — intervention group
Group type: EXPERIMENTAL
Intervention: ALG
Number of subjects: 0
Study 1677502 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3
Number of subjects: 0
Study 6341843 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase
Number of subjects: 50
Study 6341843 — intervention group
Group type: COMPARATOR
Intervention: Standard (control) therapy
Number of subjects: 50
Study 31826899 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigator intervention over 24 months
Number of subjects: 300
Study 31826899 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 300
Study 31826899 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigator intervention
Number of subjects: 300
Study 29333934 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2mm skin graft
Number of subjects: 84
Study 29333934 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3mm skin graft
Number of subjects: 84
Study 29333934 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4mm skin graft
Number of subjects: 84
Study 29333934 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 84
Study 27987585 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance erlotinib 150mg/day
Number of subjects: 643
Study 27987585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643
Study 24811601 — intervention group
Group type: EXPERIMENTAL
Intervention: PRT-201 (low dose)
Number of subjects: 89
Study 24811601 — intervention group
Group type: EXPERIMENTAL
Intervention: PRT-201 (medium dose)
Number of subjects: 89
Study 24811601 — intervention group
Group type: EXPERIMENTAL
Intervention: PRT-201 (high dose)
Number of subjects: 89
Study 24811601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 22535259 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic thyroidectomy
Number of subjects: 88
Study 22535259 — intervention group
Group type: COMPARATOR
Intervention: Conventional open thyroidectomy
Number of subjects: 88
Study 22535259 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Robotic and Conventional)
Number of subjects: 88
Study 20102883 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2185
Study 20102883 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 2185
Study 18612728 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic clinical portfolio
Number of subjects: 100
Study 18612728 — intervention group
Group type: COMPARATOR
Intervention: Traditional paper means
Number of subjects: 100
Study 15741799 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 2372
Study 15741799 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasminogen
Number of subjects: 2372
Study 15741799 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor VII:C
Number of subjects: 2372
Study 15741799 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein (a)
Number of subjects: 2372
Study 15741799 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor VII antigen
Number of subjects: 2372
Study 15741799 — intervention group
Group type: EXPERIMENTAL
Intervention: None of the measured hemostatic factors
Number of subjects: 2372
Study 12434288 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced abortion
Number of subjects: 267040
Study 12434288 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced abortion after first birth
Number of subjects: 267040
Study 12434288 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced abortion after 13 weeks gestation or before first child
Number of subjects: 267040
Study 12434288 — intervention group
Group type: COMPARATOR
Intervention: Control group (women without induced abortion)
Number of subjects: 267040
Study 11310903 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 50
Study 11310903 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with EDTA
Number of subjects: 50
Study 11310903 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 50
Study 11310903 — intervention group
Group type: COMPARATOR
Intervention: Control (ionised calcium and total magnesium)
Number of subjects: 50
Study 8804007 — intervention group
Group type: EXPERIMENTAL
Intervention: High flux dialysis membranes
Number of subjects: 0
Study 8804007 — intervention group
Group type: COMPARATOR
Intervention: Conventional dialysis
Number of subjects: 0
Study 1617983 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 150 mg/kg as a loading dose and then 20 mg/kg/hr for 6 days
Number of subjects: 66
Study 1617983 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 66
Study 1617983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 6367432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 61
Study 6367432 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 61
Study 6367432 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor and Amoxicillin
Number of subjects: 61
Study 30852365 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassion
Number of subjects: 302
Study 30852365 — intervention group
Group type: EXPERIMENTAL
Intervention: Maladaptive perfectionism
Number of subjects: 302
Study 29979205 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrotherapy modalities and specific stabilizing exercises (Training group, n = 18)
Number of subjects: 36
Study 29979205 — intervention group
Group type: COMPARATOR
Intervention: Electrotherapy modalities only (Control group, n = 18)
Number of subjects: 36
Study 27336868 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam with 5 mg droperidol
Number of subjects: 0
Study 27336868 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam with 8 mg ondansetron
Number of subjects: 0
Study 27336868 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam with 6 mg granisetron
Number of subjects: 0
Study 27336868 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam with 5 mg tropisetron
Number of subjects: 0
Study 25238860 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive computer-based home training of attention and psychological counselling
Number of subjects: 40
Study 25238860 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained)
Number of subjects: 40
Study 23015161 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised anticoagulation management system (DAWN AC)
Number of subjects: 1068
Study 23015161 — intervention group
Group type: COMPARATOR
Intervention: Warfarin dosing algorithm
Number of subjects: 1068
Study 20460558 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified MAI scoring
Number of subjects: 236
Study 20460558 — intervention group
Group type: COMPARATOR
Intervention: Beers criteria drug
Number of subjects: 236
Study 20460558 — intervention group
Group type: COMPARATOR
Intervention: MAI criteria
Number of subjects: 236
Study 20460558 — intervention group
Group type: COMPARATOR
Intervention: Standard scoring
Number of subjects: 236
Study 18946234 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 5mg
Number of subjects: 0
Study 18946234 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10mg
Number of subjects: 0
Study 18946234 — intervention group
Group type: COMPARATOR
Intervention: Pranlukast 450mg
Number of subjects: 0
Study 16205886 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (aiming at weight reduction, healthy diet, and increased physical activity)
Number of subjects: 321
Study 16205886 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intensive lifestyle intervention)
Number of subjects: 321
Study 16205886 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (in Turku subgroup)
Number of subjects: 321
Study 16205886 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 321
Study 12415535 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy delivered over the telephone (IPT-T)
Number of subjects: 30
Study 12138805 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy with ACE inhibitor perindopril
Number of subjects: 0
Study 9667344 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - Saline
Number of subjects: 50
Study 9667344 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine Group (NG) - 25 microg neostigmine
Number of subjects: 50
Study 9667344 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl Group (FG) - 25 microg fentanyl
Number of subjects: 50
Study 9667344 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-Neostigmine 10 microg Group (FNG10) - 10 microg fentanyl plus 10 microg neostigmine
Number of subjects: 50
Study 9667344 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-Neostigmine 25 microg Group (FNG25) - 25 microg fentanyl plus 25 microg neostigmine
Number of subjects: 50
Study 7857409 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional time-of-flight MR angiography
Number of subjects: 35
Study 7857409 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional phase-contrast MR angiography
Number of subjects: 35
Study 7857409 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard MR imaging
Number of subjects: 35
Study 7857409 — intervention group
Group type: EXPERIMENTAL
Intervention: Transaxial T1 MR imaging
Number of subjects: 35
Study 2649122 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine 0.25 mg
Number of subjects: 0
Study 2649122 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine 0.5 mg
Number of subjects: 0
Study 2649122 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone (Control)
Number of subjects: 0
Study 68703 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nasal spray
Number of subjects: 0
Study 68703 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal inhaler
Number of subjects: 0
Study 68703 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral syrup formulations
Number of subjects: 0
Study 68703 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 0
Study 7263138 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level transcortical DC-currents (less than 0.3 mA) applied with positive pole at vertex
Number of subjects: 0
Study 7263138 — intervention group
Group type: COMPARATOR
Intervention: Low-level transcortical DC-currents (less than 0.3 mA) applied with negative pole at vertex
Number of subjects: 0
Study 7263138 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level transcortical DC-currents (less than 0.3 mA)
Number of subjects: 0
Study 7263138 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level transcortical DC-currents
Number of subjects: 0
Study 31815717 — intervention group
Group type: COMPARATOR
Intervention: Pedometers (PED)
Number of subjects: 54
Study 31815717 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometers and Implementation Intentions (PED+II)
Number of subjects: 54
Study 30173203 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-paranormal framework for estimating causal effects
Number of subjects: 0
Study 24844540 — intervention group
Group type: EXPERIMENTAL
Intervention: ISNT rule
Number of subjects: 244
Study 24844540 — intervention group
Group type: EXPERIMENTAL
Intervention: IS rule
Number of subjects: 244
Study 24844540 — intervention group
Group type: EXPERIMENTAL
Intervention: IS rule (in eyes with CDR >0.57)
Number of subjects: 244
Study 24844540 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ISNT or IS rule and CDR >0.57
Number of subjects: 244
Study 24844540 — intervention group
Group type: EXPERIMENTAL
Intervention: Cup-to-disc ratio (CDR)
Number of subjects: 244
Study 25012813 — intervention group
Group type: EXPERIMENTAL
Intervention: Best current care plus a vocational advice service
Number of subjects: 330
Study 25012813 — intervention group
Group type: COMPARATOR
Intervention: Best current care
Number of subjects: 330
Study 22430268 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 229
Study 22430268 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 229
Study 19863501 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (initial dose 0.5‐0.8 mg kg(‐1) daily for 2 weeks followed by placebo for 4 weeks)
Number of subjects: 38
Study 19863501 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin (2.7‐4.0 mg kg(‐1) daily for 6 weeks)
Number of subjects: 38
Study 18926586 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 36
Study 18926586 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 36
Study 16076686 — intervention group
Group type: COMPARATOR
Intervention: Na-bicarbonate infusion
Number of subjects: 17
Study 16076686 — intervention group
Group type: EXPERIMENTAL
Intervention: Na-lactate infusion
Number of subjects: 17
Study 12680866 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT
Number of subjects: 35
Study 12680866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 10477008 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) before radiation therapy (XRT)
Number of subjects: 244
Study 10477008 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CT) after radiation therapy (XRT)
Number of subjects: 244
Study 8965861 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine treatment
Number of subjects: 402
Study 8965861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study 1671113 — intervention group
Group type: EXPERIMENTAL
Intervention: felodipine 5 mg with grapefruit juice
Number of subjects: 6
Study 1671113 — intervention group
Group type: COMPARATOR
Intervention: felodipine 5 mg with water
Number of subjects: 6
Study 1671113 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine 10 mg with grapefruit juice
Number of subjects: 6
Study 1671113 — intervention group
Group type: COMPARATOR
Intervention: nifedipine 10 mg with water
Number of subjects: 6
Study 1671113 — intervention group
Group type: EXPERIMENTAL
Intervention: felodipine 5 mg with orange juice
Number of subjects: 6
Study 6875007 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer pressure condition (Group one)
Number of subjects: 44
Study 6875007 — intervention group
Group type: EXPERIMENTAL
Intervention: Authority pressure condition (Group two)
Number of subjects: 44
Study 6875007 — intervention group
Group type: COMPARATOR
Intervention: No-pressure control condition (Group three)
Number of subjects: 44
Study 31691521 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-Track Treatment Initiation Counselling (FTIC)
Number of subjects: 730
Study 31691521 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (Control)
Number of subjects: 730
Study 30122196 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein (HP) diet (29% protein, 34% carbohydrate, 31% fat)
Number of subjects: 61
Study 30122196 — intervention group
Group type: COMPARATOR
Intervention: Higher-Carbohydrate (HC) diet (21% protein, 48% carbohydrate, 24% fat)
Number of subjects: 61
Study 26982115 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pyloromyotomy (LP)
Number of subjects: 19
Study 26982115 — intervention group
Group type: EXPERIMENTAL
Intervention: Open pyloromyotomy (OP)
Number of subjects: 19
Study 26982115 — intervention group
Group type: COMPARATOR
Intervention: Controls (no abdominal procedures)
Number of subjects: 19
Study 26982115 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic pyloromyotomy (LP) and Controls
Number of subjects: 19
Study 24618208 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest dose of rosuvastatin (40 mg/day)
Number of subjects: 100
Study 24618208 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on-statin extended release nicotinic acid (ER-NA)/laropiprant (1000/20 mg/day for the first 4 weeks followed by 2000/40 mg/day for the next 8 weeks)
Number of subjects: 100
Study 24618208 — intervention group
Group type: COMPARATOR
Intervention: Add-on-statin micronized fenofibrate (200 mg/day)
Number of subjects: 100
Study 23104210 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse (reported being a current smoker)
Number of subjects: 31894
Study 23104210 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued smoking
Number of subjects: 31894
Study 23104210 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model for relapse
Number of subjects: 31894
Study 23104210 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model for continued smoking
Number of subjects: 31894
Study 20702607 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year lifestyle modification regimen including a 12-week very-low-calorie diet
Number of subjects: 81
Study 20702607 — intervention group
Group type: COMPARATOR
Intervention: Routine lifestyle counseling (Control)
Number of subjects: 81
Study 17667477 — intervention group
Group type: EXPERIMENTAL
Intervention: Youths with schizophrenia (SZ)
Number of subjects: 119
Study 17667477 — intervention group
Group type: EXPERIMENTAL
Intervention: Youths with schizoaffective disorder
Number of subjects: 119
Study 17667477 — intervention group
Group type: COMPARATOR
Intervention: Comparison to published reports of adults with SZ
Number of subjects: 119
Study 16109147 — intervention group
Group type: EXPERIMENTAL
Intervention: Librarian present in PBL groups
Number of subjects: 164
Study 16109147 — intervention group
Group type: COMPARATOR
Intervention: No librarian present in PBL groups
Number of subjects: 164
Study 15218894 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gums (8 different types)
Number of subjects: 83
Study 10331155 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnourished infants (MI)
Number of subjects: 10
Study 10331155 — intervention group
Group type: COMPARATOR
Intervention: Healthy control infants (CI)
Number of subjects: 10
Study 8707125 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy (EST-R)
Number of subjects: 50
Study 8707125 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 8707125 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy (EST-NR)
Number of subjects: 50
Study 1950641 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasally administered (DesGly9‐Arg8) vasopressin (DGAVP)
Number of subjects: 103
Study 1950641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 7028050 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopiroxolamine cream (1% concentration) applied for 21 days
Number of subjects: 60
Study 7028050 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo cream) applied for 21 days
Number of subjects: 60
Study 7028050 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopiroxolamine cream (1% concentration)
Number of subjects: 60
Study 29722071 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily text messages with patient education material and treatment reminders
Number of subjects: 42
Study 29722071 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 42
Study 27305954 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 PUFA-rich fish oil (3 g/d) for 90 d
Number of subjects: 72
Study 27305954 — intervention group
Group type: COMPARATOR
Intervention: corn oil (control) for 90 d
Number of subjects: 72
Study 24682504 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg)
Number of subjects: 47
Study 24682504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 21239069 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan (weight-adjusted treatment)
Number of subjects: 174
Study 21239069 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 174
Study 20148911 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg/day)
Number of subjects: 336
Study 20148911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study 18675344 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin lyophilized dry emulsion (LDE) tablet (125 mg)
Number of subjects: 9
Study 18675344 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin lyophilized dry emulsion (LDE) tablet (125 mg) with water
Number of subjects: 9
Study 18675344 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin lyophilized dry emulsion (LDE) tablet (125 mg) without water
Number of subjects: 9
Study 18675344 — intervention group
Group type: COMPARATOR
Intervention: Immediate release (IR) tablet
Number of subjects: 9
Study 15982992 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-lactalbumin protein administration
Number of subjects: 16
Study 15982992 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 12436353 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition with fibre and lactobacillus plantarum 299
Number of subjects: 172
Study 12436353 — intervention group
Group type: COMPARATOR
Intervention: Conventional parenteral or enteral nutrition
Number of subjects: 172
Study 12436353 — intervention group
Group type: COMPARATOR
Intervention: Enteral nutrition with fibre and heat inactivated lactobacilli (placebo)
Number of subjects: 172
Study 12436353 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition with fibre and lactobacillus plantarum 299 (in liver transplant recipients)
Number of subjects: 172
Study 12436353 — intervention group
Group type: COMPARATOR
Intervention: Conventional parenteral or enteral nutrition (in liver transplant recipients)
Number of subjects: 172
Study 12436353 — intervention group
Group type: COMPARATOR
Intervention: Enteral nutrition with fibre and heat inactivated lactobacilli (placebo) (in liver transplant recipients)
Number of subjects: 172
Study 10513715 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact isolation
Number of subjects: 0
Study 10513715 — intervention group
Group type: COMPARATOR
Intervention: Not in isolation
Number of subjects: 0
Study 8881860 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide (8 micrograms.kg‐1)
Number of subjects: 12
Study 8881860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1669137 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of streptokinase (250,000 IU initial dose, 100,000 IU/h maintenance)
Number of subjects: 55